jth.14774.pdf (813.25 kB)
Download file

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D-Dimer analysis: A prospective study.

Download (813.25 kB)
journal contribution
posted on 20.05.2020, 11:45 by Florian Posch, Julia Riedl, Eva-Maria Reitter, Michael J Crowther, Ella Grilz, Peter Quehenberger, Bernd Jilma, Ingrid Pabinger, Cihan Ay
BACKGROUND:Venous thromboembolism (VTE) is a frequent complication of cancer. Elevated D-Dimer is associated with an increased risk of cancer-associated VTE. Whether changes in D-Dimer over time harbor additional prognostic information that may be exploited clinically for dynamic prediction of VTE is unclear. OBJECTIVES:To explore the potential role of longitudinal D-Dimer trajectories for personalized prediction of cancer-associated VTE. PATIENTS/METHODS:167 patients with active malignancy were prospectively enrolled (gastrointestinal: n=59 (35%), lung: n=56 (34%), brain: n=50 (30%), others: n=2 (1%); metastatic disease: n=74 (44%)). D-Dimer (median=0.8µg/mL [25th -75th percentile: 0.4-2.0]) was measured at baseline and during 602 monthly follow-up visits. Joint models of longitudinal and time-to-event data were implemented to quantify the association between D-Dimer trajectories and prospective risk of VTE. RESULTS:VTE occurred in 20 patients (250-day VTE risk=12.1%, 95%CI: 7.8-18.5). D-Dimer increased by 34%/month (0.47µg/mL/month, 95%CI: 0.22-0.72, p<0.0001) in patients who developed VTE, but remained constant in patients who did not develop VTE (change/month=-0.06µg/mL/month, 95%CI: -0.15-0.02, p=0.121). In joint modeling, a doubling of the D-Dimer trajectory was associated with a 2.8-fold increase in the risk of VTE (Hazard ratio=2.78, 95%CI: 1.69-4.58, p<0.0001). This finding was independent of established VTE risk factors. Highly personalized, dynamic predictions of VTE conditional on individual patients' D-Dimer trajectories could be obtained. CONCLUSIONS:D-Dimer increases before the onset of cancer-associated VTE, but remains constant over time in patients without VTE. This study represents proof-of-concept that longitudinal trajectories of D-Dimer may advance the personalized assessment of VTE risk in the oncologic setting.

Funding

This work was funded by an MD PhD studentship as well as a research grant from the Austrian Science Fund (FWF‐SFB‐54 Cellular Mediators linking Inflammation and Thrombosis – InThro,” grant number: F5405‐B21), a grant from the Austrian National Bank (OeNB Nr14744), and a grant from the Medical Scientific Fund of the Mayor of Vienna (Nr 17105). The entities listed above had no role in the design, analysis, interpretation, or any other aspect of this study.

History

Citation

Journal of thrombosis and haemostasis : JTH (2020)

Version

VoR (Version of Record)

Published in

Journal of thrombosis and haemostasis : JTH

Publisher

Wiley

issn

1538-7933

eissn

1538-7836

Acceptance date

14/02/2020

Copyright date

2020

Available date

19/02/2020

Language

eng